Actively Recruiting
Evaluation of Acute Endovascular Treatment in Symptomatic Isolated Cervical Internal Carotid Artery Occlusion (ETICA)
Led by University Hospital, Montpellier · Updated on 2026-01-28
200
Participants Needed
1
Research Sites
114 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Our main hypothesis is that acute EVT associated with best medical treatment is superior to best medical treatment alone, for improving clinical outcomes at 90 days, in patients with mild or severe acute ischemique stroke and diffusion-perfusion or clinical-imaging mismatch, secondary to CICAO.
CONDITIONS
Official Title
Evaluation of Acute Endovascular Treatment in Symptomatic Isolated Cervical Internal Carotid Artery Occlusion (ETICA)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years or older (no upper age limit)
- Clinical signs consistent with acute ischemic stroke
- NIHSS score greater than 5 at randomization with last seen well to randomization time less than or equal to 23 hours, or fluctuating neurological symptoms within the past 7 days
- Ischemic stroke confirmed by CT or MRI imaging, or normal imaging with suspected ischemic stroke
- Presence of mismatch: core-perfusion mismatch by DEFUSE-3 criteria if perfusion data available; otherwise clinical-imaging mismatch with ASPECTS greater than 5
- Cervical isolated internal carotid artery occlusion (CICAO) confirmed by CTA or MRA within less than 1 hour before randomization, without associated visible ipsilateral large intracranial occlusion
- Ability to start EVT procedure within 60 minutes after randomization
- Pre-stroke modified Rankin Scale score 2 or less
- Patient or representative has signed informed consent or met emergency consent criteria
You will not qualify if you...
- CICAO after recent endarterectomy (less than 1 month)
- Severe or fatal co-morbidities or life expectancy less than 6 months interfering with improvement or follow-up
- Unable or unavailable for follow-up
- Pre-existing neurological or psychiatric disease confounding evaluations
- Seizures at stroke onset that preclude accurate NIHSS assessment
- Suspected cerebral vascular disease (e.g., vasculitis)
- Pregnant or lactating women, or pregnancy planned during study
- Adult protected by law or under guardianship or curatorship
- Current participation in another investigational drug or device study
- Not affiliated with French social security system
- Known life-threatening allergy to contrast or endovascular products
- Associated middle cerebral artery stenosis 50% or more ipsilateral to CICAO
- Chronic CICAO known or suspected for 30 days or more
- Tandem occlusion with intracranial large vessel occlusion
- Associated ipsilateral large intracranial arterial occlusion
- Prior stenting of the target internal carotid artery
- Intracranial stent in same vascular territory as CICAO
- Sub-occlusive cervical ICA stenosis on CTA or MRA
- Suspicion of ICA occlusion starting at petrous, cavernous, or intracranial segment with normal cervical portion
- Known absence of vascular access
- Suspicion of aortic dissection
- Common carotid artery occlusion without ICA occlusion
- Evidence of intracranial hemorrhage on CT or MRI
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Neurology/ Stroke Unit, Hôpital Gui de Chauliac
Montpellier, Fance, France
Actively Recruiting
Research Team
C
Caroline ARQUIZAN, Medical Doctor
CONTACT
C
COSTALAT Vincent, Medical Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here